Health Decision最新文献

{"title":"Possible factors influencing the development of the number of pharmacists in China: A time series VAR model analysis from the perspective of supply and demand theory","authors":"Wei Guo, Han Zhang, Yanquan Lin, Gang Wu, Wei Li, Peng Zhang, Wan Tang, Hongdou Chen","doi":"10.54844/hd.2024.0004","DOIUrl":"https://doi.org/10.54844/hd.2024.0004","url":null,"abstract":"Objective: The supply and demand theory is used as a perspective to analyze the impact and prediction of factors such as \u0000the number of consultations in medical institutions on the number of hospital pharmacists in China. \u0000Methods: A total of 21 years of time-series data on the number of pharmacists, doctors and nurses in China’s hospitals, the \u0000number of consultations, the per capita health cost and the per capita GDP were collected from 2002 to 2022, and a vector \u0000auto-regressive model influencing the number of pharmacists in China was established to analyze the dynamic process of the \u0000influence of the number of consultations, the per capita health cost and the per capita GDP on the number of pharmacists and \u0000the direction of the influence in China. \u0000Results: There is a unidirectional Granger causality and long-term cointegration relationship between the number of consultations \u0000and the number of pharmacists, and the number of consultations will have a greater impact on the number of pharmacists in the \u0000long run and will be more stable in the later period; there is also a unidirectional Granger causality and long-term cointegration \u0000relationship between the per capita health cost and the number of pharmacists, and the per capita health cost will have a greater \u0000impact on the number of pharmacists in the short run. \u0000Conclusion: The rise in the number of pharmacists will occur along with increases in the number of visits, health costs per \u0000capita, and GDP per capita, with health costs per capita having a greater impact on the number of pharmacists in the short \u0000term, and visits and GDP per capita having a greater impact on the number of pharmacists in the long term and being more \u0000stable in the later years. \u0000Key words: number of pharmacists, vector auto-regressive model, number of consultations, per capita health costs, GDP \u0000per capita","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"37 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141652943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic literature review of quality of life among people living with HIV/AIDS in China","authors":"Liya Fan, Zhiliu Tang, Ian Jacob, Yi Chen, Huanyu Li, Yu Zhang","doi":"10.54844/hd.2024.0005","DOIUrl":"https://doi.org/10.54844/hd.2024.0005","url":null,"abstract":"Objective: This study aims to systematically characterize the health-related quality of life (HRQoL) among people living with \u0000HIV/AIDS (PLWHA) in China. \u0000Methods: The systematic literature searching was conducted from database establishment until June 28 2023 (PubMed, \u0000Embase, ISPOR, CNKI, Wanfang, and VIP Database), and health utility values were estimated using mapping algorithms. \u0000Results: 11,290 literatures were screened, of which 290 met the eligibility criteria without PLWHA restriction and covered 18 \u0000different scales. Inclusion criterion: (1) Studies investigating Chinese PLWHA, (2) Studies that utilize multi-dimensional HRQoL \u0000scales, (3) Sample size ≥100 participants, and exclusion criterion: (1) Studies not targeting on Chinese PLWHA, (2) Studies utilizing \u0000unspecified or undefined scales, (3) Studies in which the scale scores for different domains were not reported, (4) Non-research \u0000materials (editorials, correspondences, theses, etc., (5) Duplicate studies. Analysis was based on 179 studies with the most \u0000frequently used top 3 scales, including the 36-item short form survey (SF-36) in 64 (22%) studies, World Health Organization \u0000Quality of Life Questionnaire for HIV Brief Version (WHOQOL-HIV-BREF) in 58 (20%) studies, and medical outcomes study HIV \u0000health survey (MOS-HIV) in 57 (20%) studies. \u0000The 179 studies were published between 2007 and 2023. 13 studies started since 2020 after COVID-19 outbreak. 122 \u0000were non-interventional studies and 57 were prospective interventional controlled trials. 137 out of 159 studies where gender \u0000information was available reported a higher proportion of male participants. Only 3 studies published before 2020 specified the \u0000treatment regimens, all included in the National Free Antiretroviral Treatment Program (NFATP) and none was targeting integrase \u0000strand transfer inhibitor (INSTI). \u0000Across these 3 scales, non-interventional studies consistently indicated lower HRQoL in PLWHA compared to the general \u0000population, while in prospective trials it indicated HRQoL improvements through interventions like nursing care, management \u0000strategies and highly active antiretroviral therapy. \u0000Median utility values estimated from the MOS-HIV were 0.81 and 0.78, respectively, based on two mapping algorithms. \u0000Subgroup analyses indicated lower utility in AIDS patients compared to HIV-infected individuals, with differences ranging from \u00000.01 to 0.09 across various studies using different mapping algorithms. Both groups were associated with lower utility than \u0000that in general population in China. \u0000Conclusion: The overall HRQoL among Chinese PLWHA is worse than the that in general population, emphasizing the urgent \u0000need for effective treatment strategies to improve the HRQoL for PLWHA. \u0000Key words: people living with HIV/AIDS, quality of Life, China, systematic literature review","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"59 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141654531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of mirogabalin in treatment of diabetic peripheral neuropathic pain and post-herpetic neuralgia in China","authors":"Yao Wu, Libo Tao, Chang Liu, Fangxu Wang, Shuang Sun","doi":"10.54844/hd.2024.0002","DOIUrl":"https://doi.org/10.54844/hd.2024.0002","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of mirogabalin in treatment of Chinese patients with DPNP or PHN, and to discuss \u0000its reasonable pricing strategy. \u0000Methods: A cost-effectiveness analysis was performed by constructing a three-state Markov model (mild, moderate, and \u0000severe pain) to compare mirogabalin with placebo and pregabalin for DPNP or PHN patients from Chinese healthcare system \u0000perspective. The efficacy parameters were derived from randomized clinical trials (RCTs) comparing mirogabalin with placebo in \u0000the treatment of PHN or DPNP, as well as from network meta-analyses comparing mirogabalin/pregabalin with placebo RCTs. \u0000The health utility values were obtained from published literatures. Cost parameters contained cost of pregabalin, supportive \u0000care, and other medical resource utilization, were sourced from both published literature and public price database. Sensitivity \u0000analysis was conducted on key parameters to verify the stability of the results. \u0000Results: With one-year time horizon, for PHN, the incremental quality-adjusted life years (ΔQALYs) of mirogabalin compared with \u0000placebo and pregabalin were 0.048 and 0.025 respectively; For DPNP, the ΔQALYs of mirogabalin compared with placebo and \u0000pregabalin were 0.021 and 0.017 respectively. Using the national volume-based procurement price of pregabalin as a reference, \u0000with 1 and 3 times the per capita GDP in China (￥89,358, 2023) as thresholds, the daily cost of mirogabalin was found to be \u0000cost-effectiveness when it was within 1.64 times (DPNP) or 2.07 times (PHN), 2.47 times (DPNP) or 3.46 times (PHN) of the \u0000daily cost of pregabalin. One-way sensitivity showed that, utility values of mild and moderate pain, costs of mirogabalin had the \u0000biggest influence on incremental cost-effectiveness ratio. \u0000Conclusion: As a novel calcium channel modulator, the cost-effectiveness of mirogabalin is greatly influenced by the reference \u0000drug. When pricing in China, it is essential to select appropriate comparator drugs and their prices as references. \u0000Key words: cost-effectiveness, mirogabalin, diabetic peripheral neuropathic pain, postherpetic neuralgia","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"38 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141652319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The parameter variation of one-way sensitivity analysis in economic evaluation: Global systematic review","authors":"Pingping Li, Xiangyu Liu, Chen Jiang, Zeying Yang, Yihe Tian, Min Zhao, Hualing Yan, Hongchao Li","doi":"10.54844/hd.2024.0016","DOIUrl":"https://doi.org/10.54844/hd.2024.0016","url":null,"abstract":"Objective: One-way sensitivity analysis (OSA) plays a crucial role in economic evaluations (EEs), yet knowledge about parameter \u0000range and research practices is limited. Understanding these patterns is essential for reliable healthcare decision-making. This \u0000study aims to describe OSA patterns in EEs, providing insights into parameter ranges and good research practices. \u0000Methods: Systematic searches on PubMed, MEDLINE, Embase, and ScienceDirect were conducted for model-based EEs \u0000published in English (2021-2023). Neoplasm-related articles were prioritized due to their abundance. Screening, data extraction, \u0000and quality assessment were performed by two independent reviewers. Study characteristics, OSA methods, and OSA result \u0000diagrams were collected. Study quality was assessed using the Criteria for Health Economic Quality Evaluation (CHEQUE) tool. \u0000Results: Among 7,885 records, 362 articles were extracted. Economic parameters such as price per unit, packaging cost, \u0000and number of healthcare utilization were commonly varied in OSA (94%). Efficacy parameters (84%), utility parameters (79%), \u0000and safety parameters related to adverse event and complication (54%) were also frequently varied. Only 67% of the articles \u0000described parameter variation methods, 73% listed parameter change ranges, and only 34% explicitly stated the rationale \u0000behind parameter variations. A taxonomy of OSA range types was developed, including practices such as literature review, \u0000confidence intervals, practical context, clinical opinion, extreme values, percentage/distance variations, guideline provisions, \u0000author assumptions, unknown ranges/types, uncertain variations, and others. Good practices for OSA were recommended. \u0000Tornado diagrams were the most common OSA result plots (88%), accompanied by table, curve, and line chart. Method quality \u0000scored 13 out of 18 points, while reporting quality scored 12 out of 17 points. \u0000Conclusion: This systematic review revealed unsatisfactory quality in the methods and reporting of OSA in neoplasm EEs. \u0000Recommendations are provided for parameter variation methods, ranges, references, and chart presentation for future OSA \u0000studies. \u0000Key words: parameter variation, one-way sensitivity, systematic review, economic evaluation","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"30 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141655055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the application of health economics in clinical practice guidelines: A case study of breast cancer","authors":"Yashi Liu, Zixuan Wang, Mei Lu, Liying Geng, Jing Peng, Linjie Zhou, Hongchao Li","doi":"10.54844/hd.2024.0013","DOIUrl":"https://doi.org/10.54844/hd.2024.0013","url":null,"abstract":"Objective: Besides safety and efficacy evidence, economic evidence is a crucial consideration in forming recommendations \u0000for clinical practice guidelines (CPGs). However, the extent to which economic evidence is utilized in Chinese CPGs remains \u0000unclear. Our study aims to systematically analyze the application of economic evidence in CPGs, providing insights for future \u0000guideline formulation and updates. \u0000Methods: A systematic search was conducted for relevant breast cancer CPGs published from 2017 to 2023, along with breast \u0000cancer pharmacoeconomic evaluation literature from 2015 to 2017 in China. Using the Appraisal of Guidelines for Research & \u0000Evaluation Instrument II (AGREE II) to select the guideline with the highest quality score and analyze the alignment between the \u0000recommendations in the guideline and the published pharmacoeconomic evaluation results. \u0000Results: 30 breast cancer CPGs and 59 breast cancer pharmacoeconomic evaluation studies were included. The CSCO \u0000guidelines received the highest quality score. Among the included pharmacoeconomic evaluation studies, 25 were mentioned \u0000in the guideline recommendations, but economic evidence from 15 studies did not align with the guideline recommendations. \u0000Conclusion: Currently, economic evidence is seldom considered in published breast cancer CPGs in China. In future guideline \u0000formulation and updates, the involvement of health economists should be prioritized to enhance and guide the recommendations \u0000in the guidelines. \u0000Key words: clinical practice guidelines, health economic, cost-effectiveness, breast cancer","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"6 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141652159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of a predictive model for antidepressant efficacy based on machine learning","authors":"Yiyao Liu, Huitong Ni, Teng Zhi, Ziqi Zhao, Xiaoxi Zeng, Ming Hu, Zhiang Wu","doi":"10.54844/hd.2024.0012","DOIUrl":"https://doi.org/10.54844/hd.2024.0012","url":null,"abstract":"Objective: Establishing a model can accurately predict the depressive patient’s response to different drugs, thereby providing \u0000personalized treatment plans to improve treatment outcomes. \u0000Methods: Depressive patients who have taken Paroxetine hydrochloride or Venlafaxine hydrochloride or Agomelatine at a \u0000hospital in Sichuan Province are the subjects. By analyzing their medical records, medication histories, and basic information, \u0000an predictive model is constructed to predict the efficacy of antidepressant medications based on eXtreme Gradient Boosting. \u0000Results: For the prediction model of Paroxetine hydrochloride, 52 variables selected by the model were used to construct an \u0000efficient predictive model. In the training set, the model achieved an AUC value of 0.6354 and a K-S value of 0.1944, indicating \u0000good performance in correctly classifying positive and negative samples and distinguishing different predictive probability \u0000thresholds. In the validation set, the AUC was 0.6065, and K-S was 0.1847, confirming the model’s effectiveness on new data. \u0000Compared to actual clinical data, the efficacy of sertraline hydrochloride was approximately 61.9%. The model’s predictions \u0000aligned well with real-world data, reinforcing its reliability and practicality. As for venlafaxine hydrochloride, the model achieved \u0000an AUC of 0.5745 and K-S of 0.149 on the training set, while the validation set showed an AUC of 0.5298 and K-S of 0.0597. \u0000These results suggest that the model’s performance in predicting venlafaxine hydrochloride is mediocre. Comparing with \u0000clinical data, the efficacy of venlafaxine hydrochloride was approximately 68.9%, indicating a discrepancy between the model’s \u0000predictions and actual outcomes, possibly due to the uneven distribution of the training set samples. As for agomelatine, due \u0000to the insufficient number of agomelatine samples collected at the sample hospital (less than 200), an effective predictive model \u0000could not be established. \u0000Conclusion: In clinical practice, doctors can make more informed treatment decisions and achieve personalized antidepressant \u0000therapy with the assistance of this model. \u0000Key words: predictive model, machine learning, antidepressant efficacy, depressive patients, clinical practice","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"12 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141655428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacoeconomic studies on biologic agents for ankylosing spondylitis: A systematic review","authors":"Jiaqi Shi, Ziqi Zhao, Wenxin Zhou, Ming Hu","doi":"10.54844/hd.2024.0015","DOIUrl":"https://doi.org/10.54844/hd.2024.0015","url":null,"abstract":"Objective: This study aims to systematically review and assess the quality of published pharmacoeconomic studies on biologic \u0000agents for ankylosing spondylitis conducted both domestically and internationally. \u0000Methods: PubMed, Embase, and the Cochrane Library databases were searched using English keywords such as “ankylosing \u0000spondylitis” and “pharmacoeconomics.” Chinese databases, including China National Knowledge Infrastructure (CNKI) and \u0000Wanfang Database, were searched using Chinese keywords such as “ankylosing spondylitis”, “cost” and “effectiveness”. The \u0000search was conducted from the inception of the databases until February 2023. The quality of the included studies was assessed \u0000using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022) and the Quality of Health Economics \u0000Studies Instrument (QHES). Two researchers extracted data from the included studies, and descriptive analysis was performed \u0000to summarize the characteristics of the included studies. \u0000Results: A total of 24 English-language studies were included in the review. The included studies were published between 2004 \u0000and 2020, with 19 studies classified as high-quality and 5 studies as “general quality studies.” Furthermore, 18 studies (75%) were \u0000model-based pharmacoeconomic evaluations, including Markov models, mathematical models, and discrete event simulation \u0000models. In terms of economic evaluations, Tumour necrosis factor (TNF) inhibitors and IL-17 inhibitors were found to be more \u0000cost-effective compared to traditional nonsteroidal anti-inflammatory drug (NSAIDs) treatment. Factors such as the BASDAI 50 \u0000response rate and disease-related costs had varying degrees of impact on the incremental cost-effectiveness analysis results. \u0000Conclusion: The overall results indicate that, in the short-term treatment scenario, biologic agents are not cost-effective \u0000compared to traditional treatment options, but in the long-term treatment scenario, biologic agent treatment becomes more \u0000cost-effective. The most cost-effective intervention measures varied among different studies comparing different biologic agents. \u0000Key words: ankylosing spondylitis, biologicals, pharmacoeconomic evaluation, systematic review, TNFis inhibitors, IL-17 inhibitor","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"46 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141654623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current practices of model validation in economic evaluation: A systematic review in neoplasms","authors":"Pingping Li, Min Zhao, Xiangyu Liu, Hualing Yan, Zeying Yang, Chen Jiang, Yihe Tian, Hongchao Li","doi":"10.54844/hd.2024.0010","DOIUrl":"https://doi.org/10.54844/hd.2024.0010","url":null,"abstract":"Objective: Model validation is crucial for ensuring confidence in economic models, and guidelines emphasize the need for \u0000researchers to validate the pharmacoeconomic models they construct. This systematic review summarizes current practices \u0000and challenges in model validation for neoplasm economic evaluations, providing recommendations for improvement. \u0000Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we \u0000searched PubMed, MEDLINE, Embase, and ScienceDirect for model-based economic evaluations published between 2021 \u0000and 2023. The studies were screened and extracted by two researchers independently. The frequency of each model validation \u0000type was assessed, along with descriptions of specific practices, validation outcomes, and adjustments made based on the \u0000validation results. \u0000Results: Among the final 362 articles, 139 (38%) conducted model validation. External validation was the most commonly used \u0000validation method (47%), calibrating the model and comparing simulated outcomes with real-world evidence. Face validation \u0000(45%) relied on insights from clinical experts and economists. Internal validation (19%) employed tools such as the incremental \u0000mixture importance sampling (IMIS) algorithm and TreeAge. Cross validation (9%) compared data from similar events, while \u0000predictive validation (4%) used long-term follow-up data. Of the 39 studies (28%) that reported validation results, none of them \u0000made any adjustments based on the validation outcomes. The Assessment of the Validation Status of Health-Economic decision \u0000models (AdViSHE), a validation-assessment tool, was utilized in three studies for model validation. Additionally, 10% of economic \u0000evaluations lacked clear validity, while 96% had one to three validity dimensions, and only 4% had four to five dimensions. \u0000Conclusion: Most studies had limited and brief model validation practices without comprehensive descriptions. Researchers \u0000are encouraged to employ multiple validation methods and provide detailed descriptions of their validation practices, results, \u0000and adjustments. Active development and utilization of model evaluation tools should be promoted among scholars. \u0000Key words: model validation, economic evaluation, current practices, systematic review","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"89 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141652878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer","authors":"Feiyi Xiao, Wudong Xiao, Xue Li, Rui Li, Kun Zhao","doi":"10.54844/hd.2024.0009","DOIUrl":"https://doi.org/10.54844/hd.2024.0009","url":null,"abstract":"Objective: To analyze the cost effectiveness of trastuzumab detrastuzumab (T-Dxd) or trastuzumab emtezumab (T-DM1) in \u0000patients with HER2-positive advanced breast cancer who were previously treated with trastuzumab and taxanes. \u0000Methods: Based on the perspective of China’s health system, a partitioned survival model is constructed to simulate the direct \u0000medical costs, life years and quality-adjusted life years of patients throughout their life cycle. The basic scenario set by the model \u0000is: based on the data of the Asian-Pacific population in the DESTINY-Breast03 (DB03) phase III clinical trial, the experimental \u0000group and the control group were given intravenous infusion of T-Dxd and T-DM1 at a frequency of every 3 weeks respectively \u0000until the patients’ disease progressed. Clinical effect data and health utility values come from individual patient-level data of the \u0000Asia-Pacific population in the DB03 Phase III clinical trial. Direct medical costs include drug costs, follow-up treatment costs, \u0000adverse event treatment costs, medical service costs, examination and testing costs, and hospice care costs. \u0000Results: In the basic scenario, T-Dxd can reduce the risk of disease progression in patients, and compared with T-DM1, patients’ \u0000life years and quality-adjusted life years are improved. Calculated based on China’s per capita GDP in 2022 (85,698 yuan), \u0000the incremental cost-effectiveness ratio (ICER) in the case of donated drugs is within the threshold of 2 times per capita GDP. \u0000Conclusion: Trastuzumab Deruxtecan (T-Dxd) can extend the life years and improve the quality of life of patients with indications. \u0000Under the condition of drug donation, the use of T-Dxd has a comparative advantage of cost-effectiveness. \u0000Key words: cost-effectiveness analysis, trastuzumab deruxtecan, breast cancer, antibody-drug conjugate, economy","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"47 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141652867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing covariate selection and results inference in anchored matched adjusted indirect comparison method","authors":"M. Rui, Hongchao Li, Yingcheng Wang","doi":"10.54844/hd.2024.0014","DOIUrl":"https://doi.org/10.54844/hd.2024.0014","url":null,"abstract":"Indirect comparison methods become particularly prominent in pharmacoeconomic evaluations. This study delves into the \u0000anchored matched adjusted indirect comparison (MAIC) method, spotlighting the challenges of selecting appropriate covariates \u0000and distinguishing between predictive and prognostic factors. In addition, our research bridges the gap of MAIC results application \u0000inference, enhancing the methodological rigor and applicability of MAIC analyses. Through theoretical exploration and a detailed \u0000case study of toripalimab and pembrolizumab in the neoadjuvant treatment of NSCLC, we demonstrate the significant impact of \u0000covariate selection on the outcomes of pharmacoeconomic evaluations. Analyzing the individual patient data by using statistical \u0000methods alone is insufficient to identify all potential prognostic factors. Instead, a combination of previously published related \u0000research and expert consultations is necessary. The individual patient data network meta-analysis should be employed if the \u0000shared effect modifier assumption is not met to make the MAIC results be inferred for the real-world decision-making population. \u0000Key words: matched adjusted indirect comparison, covariate selection, results inference","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"37 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141653969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}